{"groups":[{"description":"Lenalidomide\n\n25 mg taken orally once daily, Days 1 - 21 of each cycle\n\nDexamethasone\n\nAdministered on Days 1, 8, 15, and 22 of each cycle:\n\nOn weeks when elotuzumab is administered:\n\n* 28 mg taken orally (3 - 24 hours prior to start of elotuzumab infusion) AND\n* 8 mg IV (at least 45 minutes prior to elotuzumab administration)\n\nOn weeks when elotuzumab is NOT administered:\n\n\\- 40 mg taken orally\n\nElotuzumab (BMS-901608)\n\n* Cycle 1 - 2: 10 mg/kg IV, Days 1, 8, 15, 22\n* Cycle 3 - 18: 10 mg/kg IV, Days 1 and 15\n* Cycle 19 and beyond: 20 mg/kg IV, Day 1","id":"FG000","title":"Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)"},{"description":"Lenalidomide\n\n25 mg taken orally once a day, Days 1 - 21 of each cycle\n\nDexamethasone\n\n40 mg taken orally, Days 1, 8, 15, and 22 of each cycle","id":"FG001","title":"Arm B: Lenalidomide + Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"8"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}],"type":"Adverse Event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"9"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"7"}],"type":"Participant request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Poor/non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"}],"type":"Administrative reason by sponsor"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"42"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"42"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"82 participants were randomized and treated."}